Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Q2 2024 Earnings Conference Call August 14, 2024 4:30 PM ET

Company Participants

Latha Vairavan - VP, Finance and Head of IR
Frank Watanabe - President & CEO
Todd Edwards - Chief Commercial Officer
Patrick Burnett - Chief Medical Officer
David Topper - CFO

Conference Call Participants

Vikram Purohit - Morgan Stanley
Tyler Van Buren - TD Cowen
Seamus Fernandez - Guggenheim Securities
Uy Ear - Mizuho Securities
Serge Belanger - Needham
Chris Shibutani - Goldman Sachs

Operator

Hello, and thank you for standing by. Welcome to Arcutis Biotherapeutics Q2 2024 Earnings Call. At this time, all participants are in a listen-only mode. After the speakers' presentation, there will be a question-and-answer session. [Operator Instructions] Please be advised that today's conference is being recorded.

I would now like to turn the call over to Latha Vairavan, Vice President, Finance and Investor Relations. You may begin.

Latha Vairavan

Thank you, Folanda. Good afternoon, everyone, and thank you for joining us today to review our second quarter 2024 financial results and business update. Slides for today's call are available on the Investors section of the Arcutis website. On the call today are Frank Watanabe, President and CEO; Patrick Burnett, Chief Medical Officer; Todd Edwards, Chief Commercial Officer; and David Topper, Chief Financial Officer.

I would like to remind everyone that we will be making forward-looking statements during this call. These statements are subject to certain risks and uncertainties and our actual results may differ. We encourage you to review all of the Company's filings with the Securities and Exchange Commission, including descriptions of our business and risk factors.

With that, let me hand the call over to Frank.

Frank Watanabe

Thanks, Latha, and thanks to everyone for joining us today. Very excited to be able to provide you with an update on the most recent quarter of our performance.

So let me start off on Slide 5 of the deck. We have continued really strong performance since our last earnings call and I continue to be delighted and very proud of the Arcutis team in our execution in the quarter and thrilled about the momentum that we're building towards the second half of the year.

Once again, we saw strong growth during the quarter in our expanding ZORYVE portfolio as healthcare providers and the patients see how ZORYVE cream and ZORYVE foam address real needs in the treatment of psoriasis and seborrheic dermatitis, respectively.